These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 18820353)

  • 1. Targeting protein acetylation for improving cancer therapy.
    Dwarakanath BS; Verma A; Bhatt AN; Parmar VS; Raj HG
    Indian J Med Res; 2008 Jul; 128(1):13-21. PubMed ID: 18820353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
    Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
    Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modifications of cell signalling and redox balance by targeting protein acetylation using natural and engineered molecules: implications in cancer therapy.
    Venkateswaran K; Verma A; Bhatt AN; Agrawala PK; Raj HG; Malhotra S; Prasad AK; Wever OD; Bracke ME; Saso L; Parmar VS; Shrivastava A; Dwarakanath BS
    Curr Top Med Chem; 2014; 14(22):2495-507. PubMed ID: 25478886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation.
    Lin T; Alam HB; Chen H; Britten-Webb J; Rhee P; Kirkpatrick J; Koustova E
    Surgery; 2006 Mar; 139(3):365-76. PubMed ID: 16546502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin-induced histone hypoacetylation: the role of reactive oxygen species.
    Kang J; Chen J; Shi Y; Jia J; Zhang Y
    Biochem Pharmacol; 2005 Apr; 69(8):1205-13. PubMed ID: 15794941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
    Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
    Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone modification enzymes: novel targets for cancer drugs.
    Kristeleit R; Stimson L; Workman P; Aherne W
    Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC inhibitors and chaperone function.
    Rao R; Fiskus W; Ganguly S; Kambhampati S; Bhalla KN
    Adv Cancer Res; 2012; 116():239-62. PubMed ID: 23088873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors in cancer therapy.
    Lane AA; Chabner BA
    J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
    Chen J; Du C; Kang J; Wang J
    Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
    Rahim R; Strobl JS
    Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.